29 studies found for:    melanoma | Open Studies | interleukin-2
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Procedure: Translational research;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Interleukin-2;   Drug: Ipilimumab infusion
2 Recruiting HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2;   Drug: Ipilimumab
3 Not yet recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
4 Unknown  A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2;   Drug: Ipilimumab
5 Recruiting IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
6 Recruiting Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Condition: Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Procedure: Radionuclide Imaging;   Biological: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
7 Recruiting T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T cells;   Biological: Interleukin-2;   Biological: Dendritic cell vaccine
8 Recruiting Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Condition: Metastatic Melanoma
Interventions: Other: Radiation therapy and high-dose IL-2;   Drug: High-dose IL-2
9 Recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
10 Not yet recruiting TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: Tumour Infiltrating Lymphocytes;   Drug: Interleukin-2
11 Recruiting T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Condition: Melanoma
Interventions: Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
12 Recruiting Vemurafenib and TIL Therapy for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Lymphodepleting chemotherapy;   Drug: TIL infusion;   Drug: Interleukin-2
13 Recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2;   Drug: Mesna
14 Recruiting Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
15 Recruiting Peginterferon and TIL Therapy for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL infusion;   Drug: Interleukin-2;   Drug: Peginterferon alfa-2b
16 Recruiting Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
17 Recruiting Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
18 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Conditions: Metastatic Renal Cell Cancer;   Malignant Melanoma, Metastatic
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
19 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
20 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years